Physician profile
Charles Maletz
NPI 1346453628
$3,402.77
in general payments reported to CMS, 2019-2025
19 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $384 · 2021: $372 · 2022: $1,274 · 2023: $283 · 2024: $515 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,258.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $701.83 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $542.95 | 2021-2025 | |
| Novo Nordisk INC | $475.38 | 2020-2024 | Wegovy |
| Lilly USA, LLC | $357.94 | 2022-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $282.84 | 2022-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $209.25 | 2020-2023 | Farxiga |
| Merz North America, INC. | $143.75 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.78 | 2022-2025 | Jardiance |
| Amgen INC. | $120.05 | 2022 | |
| Astellas Pharma US INC | $71.33 | 2024 | Veozah |
| Dexcom, INC. | $68.11 | 2025 | Dexcom G6 Transmitter |
| Nevro Corp. | $67.95 | 2022 | |
| Sanofi-Aventis U.S. LLC | $67.02 | 2022 | |
| Abbott Laboratories | $53.37 | 2024-2025 | Freestyle Libre 3 |
| Hologic Sales and Service, LLC | $32.50 | 2025 | Aptima |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $28.00 | 2022 | |
| Merck Sharp & Dohme LLC | $16.12 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.92 | 2022 | |
| Si-Bone, INC. | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Maletz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.